Navigation Links
Topaz Pharmaceuticals' Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
Date:7/11/2011

HORSHAM, Pa., July 11, 2011 /PRNewswire/ -- In a study sponsored by Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, scientists from the University of Massachusetts, Amherst presented data showing that a 0.5% ivermectin (IVM) cream formulation was active against lice eggs from permethrin resistant head lice.  The data were presented in a poster presentation on Saturday, July 9, 2011 at the 37th Annual Meeting of the Society for Pediatric Dermatology in Baltimore, Maryland.  

"These data build on our earlier work showing this ivermectin formulation is active against head lice," said John M. Clark, Ph.D., Professor of Veterinary and Animal Sciences, University of Massachusetts Amherst.  "The data suggest that a single treatment with 0.5% ivermectin cream has the potential to fully break the head louse life cycle.   If approved by the FDA, ivermectin cream has the potential to provide physicians with an attractive treatment option."  

In the study, permethrin resistant head lice were allowed to lay eggs in tufts of human hair.  Adult lice were removed and the tufts with eggs were exposed to 0.5% ivermectin cream, to vehicle only, or to unformulated, diluted ivermectin. After a 10-minute exposure, tufts were thoroughly rinsed and incubated.  Any hatched lice were placed onto new tufts and moved to a feeding cup.  The hatchability of treated eggs was not affected by ivermectin. No differences were detected between the mortality rate of eggs exposed to 0.5% ivermectin cream and those exposed to unformulated ivermectin.  The percent of hatched lice from eggs exposed to 0.5% ivermectin cream that took a blood meal, relative to eggs exposed to placebo, was significantly decreased (by 82-95%).  All hatched lice from eggs treated with 0.5% ivermectin cream died within 48 hours.  

About Ivermectin

Ivermectin is a broad-spectrum antiparasitic agent.  Its known mechanism of action is that it binds selectively to certain ion channels present in invertebrate nerve and muscle cells but not present in mammals. The resulting increase in permeability of the cell membrane causes the death of certain parasites.  First developed from a soil bacterium, widespread oral use of ivermectin, under the brand name Mectizan®, began in 1987 in sub-Saharan Africa to control river blindness (onchocerciasis) in humans.  More than one billion treatments of oral ivermectin have been administered to help alleviate the suffering caused by river blindness and lymphatic filariasis.  On June 7, 2011, FDA accepted the new drug application of Topaz Pharmaceuticals for the use of a novel topical form of ivermectin as a potential therapy to treat head lice.  This submission is presently under review by FDA.

About Topaz Pharmaceuticals

Topaz Pharmaceuticals Inc. is a privately held specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets. The company's lead investigational product is a topical cream formulation of ivermectin currently under development for the treatment of head lice infestations in children and adults which affect between six and 12 million people every year. Topaz has completed two phase 3 studies of ivermectin and has filed its new drug application for this potential indication. Topaz, headquartered in Horsham, PA, is backed by top-tier investors including Aisling Capital and Fidelity Biosciences.  For more information about Topaz Pharmaceuticals Inc., please visit www.topazpharma.com.

Contact Information
E. Blair Schoeb
Tel: 908-277-0386
blair@biotechcomm.com


'/>"/>
SOURCE Topaz Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA
2. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
3. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
4. Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
5. TOPAZ Technologies and ML Weekes & Company Announce Partnership
6. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
8. TOPAZ Technologies and Tecniplast USA Launch RFID Mobile Census
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... NEW YORK , Jan. 16, 2017 /PRNewswire/ ... global peripherally inserted central catheters market for the ... is to offer updates and information related to ... catheters market. This comprehensive market study demonstrates the ... current environment and future status of the global ...
(Date:1/16/2017)... 16, 2017   The Harrington Discovery Institute ... Ohio , has announced the 2017 recipients ... discoveries of physician-scientists whose research shows promise to ... Harrington Discovery Institute – part of The Harrington ... need in academic medicine: to advance early breakthroughs ...
(Date:1/16/2017)... and PUNE, India , January 16, 2017 ... Market Research, titled, "Vital Signs Monitoring Devices Market by Type ... projects that the global vital signs monitoring devices market size ... reach $5,491 million by 2022, growing at a CAGR of ... was the leading regional market in global vital signs ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... 2017 , ... California Southern University has named Dr. Steven Beazley University President. ... and as a core faculty member, teaching master’s and doctoral courses in the university’s ... Pepperdine University, where he earned his Doctor of Psychology degree in 1998. Dr. Beazley ...
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. ... currently offering complimentary consultations and financing for orthodontics for a limited time. Complimentary ... and learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are ...
(Date:1/16/2017)... , ... January 16, 2017 , ... St. Louisans are well-aware of the following facts ... This year’s influenza shot seems to be having no effect on keeping this particularly ... half of the people around are coughing, sneezing, or sniffling , These ...
(Date:1/16/2017)... San Francisco, CA (PRWEB) , ... January 16, 2017 , ... ... the incorporation of iTero Element, the latest in 3-D scanning device which is capable ... some of the latest advances in dentistry, such as CAD CAM restorations , ...
(Date:1/15/2017)... ... ... Whole Health Supply, LLC is announcing the release of an updated version of their ... The 2017 edition has wide jaws that will accommodate nails up to 4mm in ... diabetics. This handle is reinforced for extra strength when pressing down on dense nails which ...
Breaking Medicine News(10 mins):